UK switches Maloff, Nasonex and Otrivine

13 July 2017 - Deborah Wilkes


The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has switched Maloff Protect, Nasonex Allergy Control 0.05% Nasal Spray and Otrivine Extra Dual Relief Nasal Spray Solution to non-prescription status following public consultations.

Click tags below for more information on topics:

Glenmark MHRA

Annual Subscription Holder?

Sign in to continue reading.

Sign In

Back to Industry News

Share this page: